Screener
Bicara Therapeutics BCAX Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Bicara Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
FAQ
- What is Bicara Therapeutics's current ratio?
- Bicara Therapeutics (BCAX) reported current ratio of 13.9× in Q1 2026.
- How has Bicara Therapeutics's current ratio changed year-over-year?
- Bicara Therapeutics's current ratio decreased by 43.7% year-over-year, from 24.6× to 13.9×.
- What is the long-term trend for Bicara Therapeutics's current ratio?
- Over 2 years (2023 to 2025), Bicara Therapeutics's current ratio has grown at a -2.4% compound annual growth rate (CAGR), from 15.3× to 14.6×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Bicara Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude